Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990447 | 1.00 | IDUA (0.35) | IDUA | |
| SCHEMBL5969685 | 1.00 | IDUA (0.35) | IDUA | |
| SCHEMBL4168202 | 0.81 | IDUA (0.33) | IDUA | |
| SCHEMBL4168207 | 0.81 | IDUA (0.33) | IDUA | |
| SCHEMBL4168204 | 0.81 | IDUA (0.33) | IDUA | |
| SCHEMBL13515282 | 0.69 | — | — | |
| SCHEMBL4055843 | 0.66 | POLB (0.35) | — | |
| SCHEMBL19084377 | 0.65 | — | — | |
| SCHEMBL21324845 | 0.65 | — | — | |
| SCHEMBL22570007 | 0.63 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009118750-A1 | STEREOSELECTIVE HYDROLYSIS FOR THE RESOLUTION OF RACEMIC MIXTURES OF (+/-) -CIS-S-ACETOXY-L- (4-METHOXYPHENYL) -4- (2-FURYL) -2-AZETIDINONE, (+/-) -CIS-S-ACETOXY-L- (4-METHOXYPHENYL) -4- (2-THIENYL) -2-AZETIDINONE, OR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-10-01 | — | — | WO | disclosed |
| EP-1372636-B1 | METRONOMIC DOSING OF TAXANES FOR INHIBITING TUMOR GROWTH | BRISTOL MYERS SQUIBB CO (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1623706-A2 | Metronomic dosing of taxanes for inhibiting tumor growth | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-6916942-B2 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1251846-B1 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040143004-A1 | Metronomic dosing of taxanes | CERAM TEC AG, INNOVATIVE CERAMIC ENGINEERING (DE) | 2004-07-22 | — | — | US | disclosed |
| US-6750246-B1 | NOVEL ORALLY ACTIVE PACLITAXEL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | disclosed |
| EP-1251846-A4 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1272193-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Bristol-Myers Squibb Company (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1251846-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001056565-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143004-A1 | Metronomic dosing of taxanes | MTDH, MCL1, CCNA1 | IDUA 4121/4885 |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | CA4, CA14, CA13 | IDUA 4709/4885 |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | CA4, CA14, CDK4 | IDUA 4747/4885 |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | ABCB11, TP53, SLC10A1 | IDUA 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.